This page shows the latest rocapuldencel-T news and features for those working in and with pharma, biotech and healthcare.
Argos Therapeutics' hopes of bringing lead cancer immunotherapy rocapuldencel-T to market anytime soon have been dashed after it flunked a pivotal phase III trial. ... Rocapuldencel-T, a personalised immunotherapy that uses individual patients' tumour
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...